Compugen ((CGEN)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Compugen Ltd is currently recruiting participants for a clinical trial titled ‘An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC).’ The study aims to determine if the experimental antibody COM701 can delay the progression of ovarian cancer and assess its safety profile.
The intervention being tested is COM701, an experimental antibody administered intravenously every three weeks. It is designed to act as a maintenance treatment for relapsed platinum-sensitive ovarian cancer, potentially slowing disease progression and delaying the need for additional anti-cancer treatments.
The study is designed as a randomized, parallel-group, double-blind, placebo-controlled trial. Participants are allocated in a 1:2 ratio to receive either a placebo or COM701. The primary purpose is treatment, with triple masking applied to participants, care providers, and investigators to ensure unbiased results.
The trial began on July 21, 2025, with the last update submitted on August 4, 2025. These dates are crucial as they mark the study’s initiation and the most recent information available, indicating ongoing recruitment and data collection.
This update could positively influence Compugen’s stock performance and investor sentiment, as successful results may enhance the company’s position in the competitive oncology market. Investors should monitor this trial’s progress, considering the broader industry context and potential advancements in cancer treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.